TFF Pharmaceuticals, which recently announced that it had raised $14 million for the development of DPI formulations, has named former Arno Therapeutics CEO Glenn Mattes as its new Chief Executive Officer. Mattes’s career includes management and board positions with a number of pharmaceutical companies, including Johnson & Johnson subsidiaries Tibotec Therapeutics and Centocor (now Janssen).
TFF Pharmaceuticals Chairman of the Board Robert Mills commented, “With Glenn at the helm as our CEO, we have honored our promise to investors to build a dynamic leadership team. He is the right strategic fit for taking TFF Pharmaceuticals from inception to a strong commercial success. Glenn has a proven track record of growing and advancing transformational pharmaceutical therapeutics to market leadership worldwide.”
Mattes said, “I am excited to begin my new role at TFF Pharmaceuticals. Our breakthrough thin film freezing proprietary platform and leading-edge product portfolio address lung diseases and conditions that cause suffering and mortality throughout the world. We intend to develop and commercialize drug products that will have a positive impact globally on public health as well as significant long-term returns for our investors.”
Read the TFF Pharmaceuticals press release.
